Back

Tocotrienol decreases β-amyloid mediated toxicity in Caenorhabditis elegans model of Alzheimer's disease

Yuen, C.-W.; Abdul Halim, M.; Murugaiyah, V.; Najimudin, N.; Azzam, G.

2020-04-14 pharmacology and toxicology
10.1101/2020.04.13.040105 bioRxiv
Show abstract

Alzheimers disease (AD) is a neurological disease caused by the accumulation of extracellular senile plaques consisting of {beta}-amyloid peptide (A{beta}) in the brain. A transgenic Caenorhabditis elegans which demonstrated paralysis due to the expression of human beta amyloid A{beta}42 gene was used to study the anti-paralysis effect of mixed tocotrienols. The content of the mixed tocotrienols were 12.1% -, 2.7% {beta}-, 18.6% {gamma}-, and 8.1% {delta}-tocotrienols. Mixed tocotrienols significantly delayed the A{beta}-induced paralysis in the transgenic nematode and exhibited anti-oxidant properties towards A{beta}-generated oxidative stress. The mixture also presented potent inhibitory activities against A{beta} aggregation with an IC50 value of 600 ng/ml. It is concluded that mixed tocotrienols could potentially serve as a new therapeutic candidate for AD.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.